Advertisement
Canada markets open in 23 minutes

  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CAD/USD

    0.7314
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    78.04
    -0.44 (-0.56%)
     

  • Bitcoin CAD

    87,018.21
    +71.61 (+0.08%)
     

  • CMC Crypto 200

    1,320.56
    -44.56 (-3.26%)
     

  • GOLD FUTURES

    2,323.90
    -7.30 (-0.31%)
     

  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     

  • 10-Yr Bond

    4.4570
    -0.0320 (-0.71%)
     

  • NASDAQ futures

    18,186.25
    -9.25 (-0.05%)
     

  • VOLATILITY

    13.47
    -0.02 (-0.15%)
     

  • FTSE

    8,310.09
    +96.60 (+1.18%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • CAD/EUR

    0.6785
    -0.0007 (-0.10%)
     
MARKETS LIVE BLOG:

STOCK FUTURES TAKE BREATHER AS DISNEY EARNINGS LAND

Disney's surprise streaming entertainment profit offset by weaker TV business

Stocks in play: Cardiol Therapeutics Inc.

Baystreet.ca
·1 min read

Announced that Massachusetts General Hospital has been initiated and is eligible to enroll patients in MAvERIC-Pilot, the Company's Phase II open-label pilot study, investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis. In addition to standard safety assessments, the study is designed to evaluate improvement in objective measures of this rare disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™ and to assess freedom from pericarditis recurrence. Cardiol Therapeutics Inc. shares T.CRDL are trading up $0.04 at $1.33.

Read: